Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature

• Published in: Journal of Medical Case Reports
• Main Authors: Jaime Rubio-Perez, Ángel Ricardo Rodríguez-Perez, María Díaz-Blázquez, Victor Moreno-García, Manuel Dómine-Gómez
• Format: Article
• Language: English
• Published: BMC 2022-10-01
• Subjects: HLH; IrAE; Pharmacovigiliance; ICI
• Online Access: https://doi.org/10.1186/s13256-022-03585-3

Abstract Background Immune checkpoint inhibitors avoid inhibition of T-cell responses, upregulating antitumor immune response. Moreover, a dysregulation with hyperactive immune response can be caused, some of them underdiagnosed. Hemophagocytic lymphohistiocytosis is a rare and often fatal syndrome of uncontrolled and ineffective hyperinflammatory response that triggers an inflammatory cascade that can lead in many cases to death. Case presentation We report the case of a 67-year-old Caucasian man with stage IV lung adenocarcinoma who developed hemophagocytic lymphohistiocytosis after initiation of atezolizumab, an antagonist of programmed death-ligand 1. Even with early diagnosis and proper treatment, death occurs in approximately half of all cases reported. Conclusion Key markers are needed to better identify patients at risk of developing severe immune-related adverse events. In addition to key markers, a higher degree of suspicion and early intervention are needed to improve outcomes in acquired hemophagocytic lymphohistiocytosis, especially with the increasingly and expanding use of immune activation.